In late July 2021, NHS England opened a call for applications to the High Cost Device List (HCDL) changes for the 2022/23 National Tariff Payment System.
HCDL is an add-on reimbursement for medical devices, procedures, and in-vitro diagnostic tests. They are excluded from the calculation of unit and national prices under the National Tariff Payment System. The amount is paid on top of an HRG tariff for the device, not a procedure. This pathway will still be relevant even after the introduction of the aligned incentives and payment approach in 2022/23, as NHS-paid devices will be reimbursed in addition to the global budget at the national level.
The following key inclusion criteria should be met:
- High cost and represent a disproportionate cost relative to the relevant HRG;
- Used in a subset of cases within an HRG and/or used in a subset of providers delivering services under a specific HRG;
- Relatively high cost in terms of volume and cost.
For the 2022/2023 High Cost Device List, the application form should be filled in and sent via email (pricing@england.nhs.uk) by September 30, 2021. Nominations submitted after this date may be considered for a future tariff.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).